2021 Annual Meeting
Date: October 14-16
Location: Virtual
October 15 & 16 – Scientific & Clinical Abstract Presentations (0900-1500 CDT)
October 16 – Symposium on Epilepsy and Neoplasms (0900-1400 CDT)
Purchase Tickets
Earlybird Pricing Ends Oct 1.
Call for Abstracts
The deadline to submit has been extended to September 17th.
Scientific and clinical abstracts should be structured, concise, and should convey the essential findings. The abstract may not exceed 250 words. It should state the rationale, objectives, findings, and conclusions of the presentation. Finally, two to three learning objectives are required.
Preliminary Goals & Objectives
Scientific Abstract Presentations
Review of current clinical and basic science research pertaining to neuropathology with a focus on Canadian centres, but overall international participation. Also a platform for Canadian residents and trainees to present their recent work.
Diagnostic Case Presentations
Interactive discussion of rare and challenging neuropathological cases encountered by participants in their recent practice. Electronic slides and imaging results are distributed prior to meeting. Often includes case presentation by residents and illustrates advances in disease classification and diagnostic technique.
Overall learning objectives for the meeting
At the end of the meeting participants will:
- Describe recent developments in several areas of neuropathology with particular emphasis on the neuropathology of epilepsy and neoplasms.
- Discuss original research and challenging diagnostic cases with colleagues.
- Compare the practice of neuropathology on an individual and departmental level across Canadian centres.
Program
Please see the draft schedule below.
We will be making updates as they are confirmed.
| 0850-0900 | Opening Remarks | Peter Gould, CANP President Peter Schutz, CANP Secretary-Treasurer |
| 0900-1000 | Session 1: Scientific Abstract Presentations Moderator: TBD |
|
| 0900-0915 | Abstract 1: TBD | |
| 0915-0930 | Abstract 2: TBD | |
| 0930-0945 | Abstract 3: TBD | |
| 0945-1000 | Abstract 4: TBD | |
| 1000-1015 | Break | |
| 1015-1215 | Session 2: Neuropathology Practice I – New WHO Classification Moderator: TBD |
|
| 1015-1105 | Invited Lecture: Topic: New WHO classification with particular emphasis on infiltrative gliomas, title tba. |
Daniel Brat, MD PhD |
| 1105-1125 | Invited Lecture: Title: WHO 2021- Implementation in Canada Topic: Implications of the new WHO classification for practical molecular diagnostic work with emphasis on pediatric neoplasms. |
Cynthia Hawkins, MD PhD |
| 1125-1140 | Invited Lecture: Topic: Implications of the new WHO classification for practical molecular diagnostic work with emphasis on pediatric neoplasms, title tba. |
Stephen Yip, MD PhD |
| 1140-1215 | Panel Discussion | |
| 1215-1330 | Break | |
| 1330-1500 | Session 3: Scientific Abstract Presentations Moderator: TBD |
|
| 1330-1345 | Abstract 5: TBD | |
| 1345-1400 | Abstract 6:TBD | |
| 1400-1415 | Abstract 7: TBD | |
| 1415-1430 | Abstract 8:TBD | |
| 1430-1445 | Abstract 9:TBD | |
| 1445-1500 | Abstract 10:TBD | |
| 0900-1020 | Session 1: Diagnostic Case Presentations Moderator: TBD |
|
| 0900-0920 | Case 1 | |
| 0920-0940 | Case 2 | |
| 0940-1000 | Case 3 | |
| 1000-1020 | Case 4 | |
| 1020-1115 | Break | |
| 1115-1215 | Session 2: Diagnostic Case Presentations Moderator: TBD |
|
| 1115-1135 | Case 5 | |
| 1135-1155 | Case 6 | |
| 1155-1215 | Case 7 | |
| 1215-1330 | Break | |
| 1330-1415 | Session 3: Neuropathology Practice II – Forum Invited topics for discussion and follow up of neuropathology practice topics from last year. Moderator: TBD |
|
| 1415-1515 | Session 4: Diagnostic Case Presentations Moderator: TBD |
|
| 1415-1435 | Case 8 | |
| 1435-1455 | Case 9 | |
| 1455-1515 | Case 10 | |
| 0900-0910 | Welcome & Introductions and Pre-Test Moderator: Peter Gould |
|
| 0910-1000 | David Robertson Invited Lecture: Topic: New insights into epilepsy associated neoplasms, title tba. Moderator: Peter Gould |
Eleonora Aronica, MD PhD |
| 1000-1050 | Jerzy Olszewsky Invited Lecture: Topic: SUDEP, title tba Moderator: Peter Gould |
Maria Thom, MD |
| 1050-1110 | Break | |
| 1110-1200 | Gordon Mathieson Invited Lecture: Title: Why are some cerebral malformations more epileptogenic than others? Clues from developmental neuropathology Topic: Epileptogenic mechanisms in cortical malformation. Moderator: TBD |
Harvey Sarnat, MD PhD |
| 1200-1250 | Invited Lecture: Topic: Epilepsy as connectivity disease and surgical implications, title tba. Moderator: TBD |
George Ibrahim, MD PhD |
| 1250-1320 | Post-Test; Resident prizes; Concluding remarks Moderator: Peter Gould, Peter Schutz |
|
Invited Lecturers
Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.
Invited Lecturers
Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.
Mary Tom Award
Best Clinical Paper
Winners will be announced after the annual meeting
Morrison H. Finlayson Award
Best Basic Science
Winners will be announced after the annual meeting
Scientific Abstracts
Abstract #1
Abstract 1- 0900-0915 Category: Clinical At the end of the session,participants will be able to: Identify the presence of this molecular alteration in low grade gliomas Use this important information to correlate it with clinical implications Presenter My name is...
Abstract #2
Abstract 2- 0915-0930 Category: Clinical At the end of the session,participants will be able to: Understand the principal neuropathological feature that distinguishes primitive neuroblastoma from ganglioneuroblastoma Recognize the immunocytochemical neuronal markers...
Abstract #3
Abstract 3- 0930-0945 Category: Clinical At the end of the session,participants will be able to: The diagnosis of malignant astrocytomas based on molecular features of IDH1 mutation may be unaccompanied by year-over-year tumor growth despite no treatment with either...
Abstract #4
Abstract 4- 0945-1000 Category: Clinical At the end of the session,participants will be able to: Optimal utilization of small biopsy specimen is very important in order to facilitate complete molecular work up, from frozen section to making a diagnosis. Specific...
Abstract #5
Abstract 5- 1300-1315 Category: Basic Science At the end of the session,participants will be able to: Introduce a computer-based method for the morphometric evaluation of alpha-synuclein inclusions in Multiple System Atrophy (MSA) brains. Demonstrate variability in...
Abstract #6
Abstract 6- 1315-1330 Category: Clinical At the end of the session,participants will be able to: Understand the relationship between clinical manifestations and neuropathology in AD Describe the characteristics that are associated with cognitive resilience in AD...
Abstract #7
Abstract 7 - 1330-1345 Category: Basic Science At the end of the session,participants will be able to: To understand the basis of abnormal iron accumulation in vulnerable regions of PSP diseased human brains. To understand the patterns of pathological iron...
Abstract #8
Abstract 8- 1345-1400 Category: Basic Science At the end of the session,participants will be able to: To appreciate the value of proteomics in research To understand desmin aggregation in Friedrich cardiomyopathy To understand the cytoskeletal abnormalities in...
Abstract #9
Abstract 9- 1400-1415 Category: Clinical At the end of the session,participants will be able to: To understand the discrepancy between clinical presentation of concussion (i.e. long-term severe symptoms including dementia) and pathological diagnosis of CTE (minimal...
Abstract #10
Abstract 10- 1415-1430 Category: Basic Science At the end of the session,participants will be able to: Mechanisms of astrogliosis involved in the CNS reaction to the neurotrauma in the model of the SCI. Novel interpretation of the role of astrogliosis in histologic...
Diagnostic Case Studies
Case #1
Presentation Time: 0900-0915 Maryam Bintumar1, Sepideh Mokhtari2 and Robert J.B. Macaulay1 1 Department of Pathology, Moffitt Cancer Center, Tampa FL, USA 2 Department of Neuro-Oncology, Moffitt Cancer Center, Tampa, FL USA Case 1: Progressive polyneuropathy in...
Case #2
Presentation Time: 0915-0930 Suzy E. Kosteniuk 1, Kristopher D. Langdon 1. Christopher Dunham 2, 3, Sumit Das 4 Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, AB, Canada Division of Anatomic Pathology, British Columbia Children’s...
Case #3
Presentation Time: 0930-0945 Roman E. Zyla1, Brendan C. Dickson1,2, Andrew F. Gao1,3 1. Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto ON, Canada 2. Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto ON,...
Case #4
Presentation Time: 0945-1000 B. Joseph MD, J. Maguire MB, BCh, BAO. Division of Neuropathology, Dept. of Pathology and Laboratory Medicine, Vancouver General Hospital, University of British Columbia Case 4: A Clinical Calamity Presentation: 29 year old female...
Case #5
Presentation Time: 1030-1045 Alexander S. Easton Department of Pathology, Dalhousie University, Halifax, NS, Canada Case 5: Acute presentation of an unusual frontal white matter disease This 56 year old black woman, a retired music teacher, presented 13 May...
Case #6
Presentation Time: 1045-1100 Bradley M. Chaharyn and Peter W. Schutz Division of Neuropathology, University of British Columbia, Vancouver, BC Case 6: Diagnostic case presentation A 45-year-old female presented with a two-year history of slowly progressive...
Case #7
Presentation Time: 1100-1115 Hao Li1, Lee-Cyn Ang1 1Pathology and Laboratory Medicine, London Health Sciences Centre, Schulich School of Medicine and Dentistry, Western University, London ON Canada Case 7: Diagnostic case presentation 34-year-old male....
Case #8
Presentation Time: 1115-1130 Christopher Newell 1, Gregory A. Kline 2, Jeffrey T. Joseph 1 1 Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, AB, Canada 2 Division of Endocrinology, Department of Medicine, University of Calgary,...
Continuing Professional Development Information
This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, and approved by theCanadian Association of Neuropathologists. You may claim a maximum of 13.25 hours (credits are automatically calculated)
Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association, physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits. Information on the process to convert Royal College MOC credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.
In keeping with CMA guidelines, program content and selection of speakers are the responsibility of the program committee. Support is directed towards the costs of the course and not to individual speakers. No commercial support has been solicited for this meeting.